Medizinische Universität Graz - Research portal
Selected Publication:
Bergeron, C; Tafese, T; Kerbl, R; Craft, A; Mann, J; Frappaz, D.
European Experience with Screening for Neuroblastoma Before the Age of 12 Months
MED PEDIAT ONCOL 1998 31: 442-449.
Doi: 10.1002/(SICI)1096-911X(199811)31:5<442::AID-MPO10>3.0.CO;2-V
Web of Science
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Kerbl Reinhold
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- If neuroblastoma is a homogeneous disease, a screening program may be appropriate to detect the condition during the preclinical phase, before symptomatic disease, and it may decrease the overall mortality rate. Six pilot Euro pean screening studies were performed in infants to study the feasibility (Newcastle, U.K.; Birmingham, U.K.; Stuttgart, Germany; Hamburg, Germany; Lyon, France; Graz, Austria). Each country took advantage of its national health care system to undertake the screening program. Screening procedures were gas chromatography-mass spectroscopy (CC-MS), enzyme immunoassays (EIA), and high-performance liquid chromatography (HPLC), with electrochemical detection (ECD) in the various programs. A total of 434,538 infants were screened from 922,171 live births in Europe. A compliance rate exceeding 70% was achieved by three of the European studies: Newcastle (91%), Stuttgart (76%), and Lyon (81%). A total of 53 true-positive cases were found, with low stage in 66% of cases. The overall survival of these true-positive cases is 96%; 15 false-negative cases were found in whom the mean delay to diagnosis was 28 months after screening (range, 5-42 months), and 13 of the 15 cases had advanced-stage disease (10 had stage 4, and 3 had stage 3). Six false-negative cases are already dead, 2 are in partial remission, and 7 are in complete remission. Overdiagnosis is suspected, because of the observed cumulative incidence rate, the good prognostic features of true-positive cases and the bad prognostic features of false-negative cases. Screening for neuroblastoma in early infancy is unlikely to lead to benefit. Med. Pediatr. Oncol. 31:442-449, 1998. (C) 1998 Wiley-Liss, Inc.
- Find related publications in this database (Keywords)
- Neuroblastoma
- Screening
- Children
- Cancer